1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of pharmacokinetic model-based ATG dosing to improve survival through enhanced immune reconstitution in patients undergoing ex vivo CD34-selected allogeneic HCT (PRAISE-IR)
    Meeting Abstract

    Scordo, M.; Perales, M. A.; Mauguen, A.; Lin, A.; Kunvarjee, B.; Bieler, J.; Nguyen, L. K.; Paes Pena, M.; Cho, C.; Gyurkocza, B.; more...
    Bone Marrow Transplantation (2024)

    Fulltext@MSK | Save
  • The Disease Risk Stratification System (DRSS): Validation and refinement in a contemporary acute leukemia cohort - An ALWP EBMT study
    Meeting Abstract

    Shouval, R.; Labopin, M.; Fein, J.; Versluis, J.; Stelljes, M.; Kröger, N.; Blau, I. W.; Schroeder, T.; Eder, M.; Blaise, D.; more...
    Bone Marrow Transplantation (2024)

    Fulltext@MSK | Save
  • Large-scale TCR deep sequencing reveals a T cell diversity bottleneck with post-transplant cyclophosphamide with implications for efficacy and toxicity: Results of the BMT-CTN 1801 study
    Meeting Abstract

    Kean, L.; Siegel, S.; Schmalz, J.; Bien, S.; DeWolf, S.; Dong, J.; Scheffey, D.; Sanders, C.; Robins, H.; Applegate, K.; more...
    Bone Marrow Transplantation (2024)

    Fulltext@MSK | Save
  • Site-specific responses and extranodal involvement implications in large B-cell lymphomas treated with CD19-CART therapy
    Meeting Abstract

    Luna de Abia, A.; Devlin, S. M.; Flynn, J.; Corona De Lapuerta, M.; Luttwak, E.; Landego, I.; Dahi, P. B.; Lin, R. J.; Parascondola, A.; Palomba, M. L.; more...
    Bone Marrow Transplantation (2024)

    Fulltext@MSK | Save
  • Ocular findings in patients with histiocytosis and association with clinical and molecular features
    Journal Article

    Francis, J. H.; Reiner, A. S.; Canestraro, J.; Rampal, R. K.; Abramson, D. H.; Diamond, E. L.
    British Journal of Ophthalmology (2024)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3
    Meeting Abstract

    Scheid, C.; Rodriguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Global response score correlates with quality of life in cutaneous T-cell lymphoma
    Meeting Abstract

    Khan, N.; Drill, E.; Moskowitz, A.; Shinohara, M.; Larocca, C.; Querfeld, C.; Zain, J.; Horwitz, S.
    Quality of Life Research (2024)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) vs standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in high-risk subgroups
    Meeting Abstract

    Raab, M. S.; Patel, K.; Rodríguez-Otero, P.; Manier, S.; Baz, R.; Cavo, M.; Callander, N.; Costa, L. J.; Moreau, P.; Solomon, S. R.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in the modified intent-to-treat (mITT) population
    Meeting Abstract

    Scheid, C.; Manier, S.; Ailawadhi, S.; Rodríguez-Otero, P.; Arnulf, B.; Patel, K.; Solomon, S. R.; Baz, R.; Jagannath, S.; Raje, N.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Borchmann, P.; Morschhauser, F.; Dahiya, S.; Palomba, M. L.; García-Sancho, A. M.; Ortega, J. L. R.; Kuruvilla, J.; Jäger, U.; Cartron, G.; Izutsu, K.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save